Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Bioventus's EV/EBITDA was 12.6× on Nov 11, 2026, against 12.0× a year earlier. Over the last 3 years it ranged from 8.8× to 220.3×, with a median of 18.9×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	12.6×	+0.7
2025	Dec 31, 2025	11.9×	−146.1
2024	Dec 31, 2024	158.0×	+137.8
2022	Apr 29, 2022	20.2×	–

Where these numbers come from

Parsed from the XBRL in Bioventus's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BVS.

Compare: BVS vs OFIX · BVS vs AORT · BVS vs ATRC · BVS vs ANIK · BVS vs ATEC

Revenue growth3.9% · median 13.8%

Gross margin68.7% · median 70.9%

Operating margin9.7% · median -2.1%

Net margin9.8% · median -3.7%

Company	Revenue	Growth
ATEC	$839.72M	+15.3%
OFIX	$835.41M	+2.1%
ATRC	$589.80M	+13.8%
BVS	$585.64M	+3.9%
AORT	$481.88M	+14.0%
ANIK	$123.43M	+9.4%

Company

Next earnings (est.): Mar 4, 2027, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 930
Held by institutions: 71.2%
Auditor: GRANT THORNTON LLP
SEC CIK: 1665988

Advertisement
300 × 250

See a number that looks wrong?

Bioventus EV/EBITDA

EV/EBITDA at the end of each year

More Bioventus figures